Full-Time

Senior Staff Accountant

Posted on 8/20/2024

Telix Pharmaceuticals

Telix Pharmaceuticals

501-1,000 employees

Develops targeted radiation therapies for cancer

No salary listed

Senior

Fishers, IN, USA

Candidates should expect to be in the office at minimum 3 days per week; local candidates are preferred.

Category
Cost Accounting
Financial Accounting
Financial Analysis
Management Accounting
Accounting
Required Skills
SAP Products
Requirements
  • Bachelor's degree in Finance or Accounting, MBA preferred.
  • Certified Public Accountant or equivalent certification highly preferred.
  • 5-7 years of progressive accounting experience, including a solid background in financial reporting, general ledger management, and month-end/year-end processes.
  • Experience with international accounting standards or working in a global organization.
  • Strong proficiency in SAP or other accounting software programs.
  • Excellent analytical, problem-solving, and detail-oriented skills.
  • Demonstrated involvement in mergers and acquisitions with an understanding of closing/purchase price accounting transactions.
  • Excellent communication and organizational skills.
Responsibilities
  • Ensure timely recording, analyzing and reporting of accounting transactions.
  • Ensure full and complete balancing of intercompany transactions to allow for proper elimination at group level.
  • Co-lead and participate in month-end and year-end close activities, including journal entry posting, reconciliations, accruals, and financial reporting.
  • Complete inventory confirmations, journal entries and transfer pricing transactions within the accounting system.
  • Partner with FP&A team to analyze monthly activity to explain reporting variances and enhance forecasting.
  • Collaborate with various teams and team members regarding SOX compliance activities, internal and external audits.
  • Provide back-up and support for other accountants and ensure proper cross training.
  • Assist in purchase price accounting transactions and opening balance sheet for mergers and acquisitions.
  • Understand and support revenue recognition in accordance with ASC606 and IFRS 15.
  • Understand, support and record transactions related to right our use assets, leases, ASC842.
  • Understand, support, record and reconcile transactions related to various tangible and intangible assets.
  • Develop and maintain documentation related to accounting policies and procedures, ensuring alignment with company guidelines and best practices.
  • Support the review of financial statements for a variety of legal entities, in multiple currencies, to ensure completeness and accuracy of financial data in compliance with accounting standards, GAAP & IFRS.
  • Stay abreast of changes in accounting standards and regulations, evaluating their impact on the organization, and implementing necessary adjustments.
  • Collaborate with stakeholders to provide guidance on financial principles and address any related inquiries or concerns.
  • Embody a shared services mindset to work cross functionally and with a variety of teams.
  • Participate in cross-functional initiatives and projects aimed at improving processes, systems, and controls.
  • Ensure adherence to regulatory requirements, accounting standards, and internal controls related to revenue recognition and rebate programs.
  • Assist in internal and external audits by providing documentation, explanations, and support related to revenue and revenue related processes, controls, and compliance.
  • Implement corrective actions and improvements based on audit findings and recommendations.
  • All other duties as assigned, which may change from time to time to meet business needs.
Telix Pharmaceuticals

Telix Pharmaceuticals

View

Telix Pharmaceuticals develops and sells products for diagnosing and treating cancer and rare diseases using targeted radiation. Their products aim to enhance treatment decisions and offer personalized therapy for conditions that lack effective solutions. The company focuses on areas such as prostate and kidney cancers, glioma, sarcoma, and bone marrow conditioning. Telix operates a global supply chain to manufacture and distribute its specialized products to healthcare providers and patients. Unlike many competitors, Telix emphasizes sustainability, patient care, and ethical practices in its operations. The company's goal is to improve the quality of life for patients while creating sustainable value for all stakeholders.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Melbourne, Australia

Founded

2015

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA's Priority Review for TLX250-CDx boosts potential for early market entry in 2025.
  • Illuccix's approval in the UK and Europe meets growing demand for prostate cancer imaging.
  • Acquisition of ImaginAb's platform expands Telix's reach in radiotherapeutic technology.

What critics are saying

  • Increased competition in PSMA-PET imaging may impact Telix's market share.
  • Potential supply chain disruptions for gallium-68 could affect Illuccix's availability.
  • Regulatory challenges may hinder TLX250-CDx's expansion beyond the U.S. and Europe.

What makes Telix Pharmaceuticals unique

  • Telix specializes in molecularly-targeted radiation therapy for cancer and rare diseases.
  • The company focuses on urologic, neuro-oncology, and musculoskeletal oncology therapeutic areas.
  • Telix integrates sustainability and ethical practices into its operations and patient care.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Annual Performance Bonus

Equity-Based Incentive Program

Paid Vacation

Paid Wellness Days

Hybrid Work Options

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

-2%
Telix Pharmaceuticals
Mar 19th, 2025
EAU25: Telix presents at Europe's largest urological event

Join Telix this week at the 40th Annual European Association of Urology Congress (EAU25) being held in Madrid, Spain.

PR Newswire
Feb 26th, 2025
Fda Accepts Bla For Tlx250-Cdx (Zircaix®) For Kidney Cancer Imaging, Grants Priority Review

MELBOURNE, Australia, Feb. 26, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the United States (U.S.) Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for its breakthrough investigational kidney cancer PET[1] imaging agent TLX250-CDx (Zircaix®[2], 89Zr-DFO-girentuximab), granted a Priority Review and provided a PDUFA[3] date of 27 August 2025, paving the way for a U.S. commercial launch in 2025.If approved, TLX250-CDx will become the first commercially available imaging agent to accurately and non-invasively diagnose and characterize clear cell renal cell carcinoma (ccRCC), the most common and one of the most aggressive sub-types of kidney cancer. It works by specifically binding to carbonic anhydrase IX (CAIX), a validated target protein expressed on 95% of ccRCC cells to produce images with high tumor-to-background ratio and high intra- and inter-reader consistency.The BLA is based on Telix's successful global Phase 3 ZIRCON[4] study, which demonstrated a sensitivity of 86%, specificity of 87% and a positive predictive value (PPV) of 93% for ccRCC, including in very small, difficult-to-detect lesions[5]. The results of this study were published in The Lancet Oncology in September 2024, in a peer-reviewed manuscript by Professor Brian Shuch (University of California, Los Angeles, UCLA) and colleagues[6]. The paper outlines the critical unmet need for a new, non-invasive technique that can accurately detect and differentiate ccRCC from other renal masses in patients and concluded that TLX250-CDx meets this need and 'has the potential to be practice changing.'Kevin Richardson, Chief Executive Officer, Precision Medicine, said, "We are delighted that the FDA has accepted this BLA as it moves us one step closer to bringing our breakthrough product to patients

The Manila Times
Feb 13th, 2025
Telix to Showcase Urology Pipeline at Upcoming ASCO Genitourinary Cancers Symposium (ASCO GU 2025)

Telix to showcase urology pipeline at upcoming ASCO Genitourinary Cancers Symposium (ASCO GU 2025).

PR Newswire
Feb 12th, 2025
Illuccix® Approved In The United Kingdom

MELBOURNE, Australia, Feb. 12, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the United Kingdom (UK) Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the Marketing Authorization Application (MAA) for its prostate cancer PET[1] imaging agent Illuccix® (kit for the preparation of gallium-68 gozetotide injection).Illuccix is indicated in the UK for the detection and localization of prostate-specific membrane antigen (PSMA)-positive lesions in adults with prostate cancer, using PET. PSMA-PET imaging[2] represents a major advancement in prostate cancer management, largely replacing conventional imaging methods (bone scan, CT[3] scan) as the standard of care after initial diagnosis and biochemical recurrence (BCR). Global guidelines highlight the superior accuracy of PSMA-PET for the staging of primary disease and evaluation of BCR/biochemical persistence (BCP)[4].Gary Cook, MD, Professor of Molecular Imaging at Kings College London School of Biomedical Engineering & Imaging Sciences, commented, "PSMA-PET supply shortages in the UK and Europe have escalated over the past 12 months as demand increases, which has led to delays for men in urgent need of a scan to direct clinical management. It is great news that Telix can now help address this unmet need and improve equity of access in the UK through their Illuccix imaging agent and network distribution model."Raphaël Ortiz, Chief Executive Officer, Telix International added, "PSMA-PET imaging is one of the most important developments in prostate cancer detection in recent years and we are delighted that we can now bring Illuccix to physicians and their patients across the UK. A key advantage of Illuccix is that the radioisotope (gallium-68) can be produced using a generator locally, taking just a few minutes with minimal equipment

PR Newswire
Jan 22nd, 2025
ImaginAb's Biologics Platform Acquired by Telix

ImaginAb, Inc. has agreed to sell its next-generation therapeutic candidates, biologics technology platform, and research facility to Telix Pharmaceuticals. Post-transaction, ImaginAb will focus on its CD8 ImmunoPET, in Phase 2 trials, and its prostate cancer imaging agent. The sale allows Telix to explore new disease areas with radiotherapeutic technology. Jefferies LLC and Stifel, Nicolaus & Company advised on the transaction.

INACTIVE